ADC Therapeutics Clinical Trial Data
ADC Therapeutics announced updated clinical data for ZYNLONTA from several trials, including the LOTIS-7 Phase 1b study which showed an 88.7% overall response rate and 75.3% complete response rate in relapsed or refractory large B-cell lymphoma. The data, which will be presented at the ASH Annual Meeting, also highlighted a 93% ORR in marginal zone lymphoma and results from the Phase 3 LOTIS-5 study. These findings support the company's plans to advance ZYNLONTA into Phase 3 studies for expanded indications.